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Objective
To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC] and
renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and
geographical variation.
Patients and Methods
This was an international multicentre prospective observational study. We included patients aged ≥16 years, referred to
secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded.
We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of
haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age,
type of haematuria, sex, smoking, hospitals, and countries.
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Results
Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall
adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3–34.1), bladder cancer (n = 1951)
24.7% (95% CI 19.1–30.2), UTUC (n = 128) 1.14% (95% CI 0.77–1.52), renal cancer (n = 107) 1.05% (95% CI 0.80–1.29),
and prostate cancer (n = 124) 1.75% (95% CI 1.32–2.18). The odds ratios for patient risk markers in the model for all
cancers were: age 1.04 (95% CI 1.03–1.05; P < 0.001), visible haematuria 3.47 (95% CI 2.90–4.15; P < 0.001), male sex 1.30
(95% CI 1.14–1.50; P < 0.001), and smoking 2.70 (95% CI 2.30–3.18; P < 0.001).
Conclusions
A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We
are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary
care, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible
haematuria was the strongest predictor for urinary tract cancer.
Keywords
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INTRODUCTION
Urinary tract cancers are associated with a significant
morbidity and mortality, and their prevalence varies globally
[1,2]. The majority of urinary tract cancers consist of bladder
cancers, with the minority consisting of upper tract urothelial
carcinoma (UTUC) and renal cancers [3].
Haematuria is the most common presentation of suspected
urinary tract cancers and is the leading cause of referral to
secondary care amongst the urological cancer pathways [4,5].
This poses a huge global health burden [6]. Haematuria can be
classified into visible (macroscopic or gross) haematuria (VH)
and non-visible (microscopic or dipstick) haematuria (NVH).
Other causes of haematuria should be considered including
benign pathology and uncommonly, prostate cancer in men.
There is a higher rate of urinary tract cancer in patients with
VH compared to NVH, and this is a known predictor of
urinary tract cancer [7–9]. Other known risk markers are
important to consider including age, smoking and male sex,
which have been associated with urinary tract cancer, with
variation in the reported strength of association [10–12].
Cancer prevalence data can inform clinical guidelines on
referral of patients for investigation of suspected urinary tract
cancer, as shown by the systematic review used for informing
AUA guidelines [13]. The majority of the evidence used is
from secondary care data, including several prospective and
retrospective cohort studies [3,8,9,14]. However, these have
been smaller and geographically limited studies. Furthermore,
they only report crude estimates of cancer prevalence and
have not adjusted for well-known risk markers or
geographical variation in multicentre studies.
The IDENTIFY study is the largest prospective study of
patients referred with suspected urinary tract cancer, which
evaluated a globally diverse population. Our primary objective
was to assess the contemporary prevalence of bladder cancer,
UTUC, renal cancer and prostate cancer in patients referred
to secondary care with suspected urinary tract cancer. Our
secondary objectives were to assess the prevalence of these
cancers in patients referred with VH and NVH across
different age groups, sex and smoking status, and report the
adjusted prevalence to inform evidence-based updates of
referral guidelines.
PATIENTS AND METHODS
Study Design and Setting
The IDENTIFY study was an international prospective cohort
study conducted by the British Urology Researchers in
Surgical Training (BURST) collaborative group [15]. The
protocol for the study has been published [16]. The study
evaluated patients referred to secondary care for suspected
urinary tract cancer, predominantly with haematuria.
Participating collaborators completed a registration survey
describing their typical protocol for the investigation of
haematuria at their hospital (Appendix S1). Patient data were
obtained from hospital records of consecutive patients
attending a secondary care ‘haematuria clinic’ for a diagnostic
cystoscopy between December 2017 and December 2018.
Patients were followed-up until their haematuria
investigations were concluded and a diagnosis confirmed or
ruled out, as per the judgement of the clinical care team. The
study was closed in February 2019. We report this study
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according to the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) guidelines (Appendix S1)
[17].
Participants
We included patients aged ≥16 years, with haematuria or
with no haematuria (NH), referred to a urologist for the
investigation of suspected urinary tract cancer (defined as
bladder cancer, UTUC or renal cancer). Patients were
excluded if they had a previous or known diagnosis of
primary urological cancer or were undergoing investigations
for recurrence of a primary urological cancer.
Outcomes
The primary outcome was the prevalence of bladder cancer,
UTUC, renal cancer and prostate cancer in patients referred
to secondary care with suspected urinary tract cancer. We
define cancer prevalence as detected cases within the defined
population (patients referred to secondary care), which is
consistent with terminology used in previous published
literature [8]. Prostate cancer typically follows a different
referral pathway and is not included in our definition of
suspected urinary tract cancer; however, we report its
prevalence of cancer based on its identification in the pilot
study [16]. Our secondary outcomes were the prevalence of
these cancers in patients stratified by and adjusted for type of
haematuria, age, sex and smoking status, as these are well-
established markers of cancer.
Diagnostic Criteria: Cancer Classification
Patients were classified as being cancer positive or cancer
negative for the calculation of prevalence. We determined the
case definitions for bladder cancer, renal cancer, UTUC and
prostate cancer before analysis of prevalence (Table S1).
Pathological definitions were based on the WHO cancer
classification system [18,19]. Patients with histological or
clinical evidence for cancer after multidisciplinary team
(MDT) review were classified as cancer positive, whilst those
with negative investigations for cancer, or without sufficient
clinical evidence for a finding to be determined as cancer
were classified as cancer negative. Definitions were in
accordance with current clinical practice in the management
of patients with urinary tract cancer.
Data Collection
Data collected included the reason for referral, baseline
demographic information, clinical history, urine analysis,
cytology, imaging findings, cystoscopy findings,
histopathology from biopsies or surgery, and MDT decisions
[16]. Type of haematuria was determined by the primary care
referral letter and/or the history obtained from the patient at
the time of assessment in secondary care. NVH was defined
by a trace or more on urine dipstick, or >3 red blood cells/
high-power field [20]. Smoking status was categorised into
current smoker, ex-smoker, and never smoked. All site data
were verified for completeness by an independent quality
control team.
Sample Size
Sample size was determined a priori. Based on the overall
prevalence of urological malignancy of 12% from our pilot
study [16], a minimum sample size of 5000 patients was
required to give a 95% CI with a precision of  0.01% for
the estimate of cancer prevalence.
Statistical Analysis
Unadjusted estimates of urinary tract cancer prevalence
were calculated as proportions of the total number of
patients with the target disease in a cohort (total number
of patients at risk). The CIs were calculated using the
Wilson method [21,22]. Patients with NH were included in
this analysis for completeness. These patients typically have
an incidental finding of cancer on imaging and are referred
through the haematuria pathway for confirmation. However,
they were not included in the secondary outcomes as we
deemed them a distinct patient group. We also estimated
prevalence separately for patients with VH and NVH.
NVH was not subdivided into asymptomatic NVH and
symptomatic NVH, as there is no agreement on which
symptoms are included in symptomatic NVH [23]. Within
each type of haematuria, we stratified prevalence by cancer
type, sex, age group, and smoking status. The first age
group was defined as aged <35 years to reflect the lowest
age threshold used in international guidelines [3,24]. Age
bins of 5 years were chosen, as this was the common
denominator to match different international guideline age
thresholds. Analyses of prostate cancer only included male
patients.
We adjusted the cancer prevalence for four predetermined
risk markers (type of haematuria, age, sex, and smoking)
using a mixed-effects logistic regression model that
included country and centre as random effects to adjust for
country and centre variation in prevalence. Age was
analysed as a continuous variable. Risk markers were
chosen on basis of prior evidence and biological plausibility
for their association with urinary tract cancer detection.
Adjusted estimates of prevalence were obtained from these
models.
We did not impute missing data and all analyses were
performed using Stata version 16.1 (StataCorp, College
Station, TX, USA). A P < 0.05 was deemed statistically
significant.
442
© 2021 The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International
Khadhouri et al.
Data Handling and Ethics
Anonymised patient data were securely collected from
routinely documented information during the investigation of
haematuria and patient records were accessed only by the
direct clinical care team. In the UK, the coordinating centre,
The Royal Devon and Exeter NHS Foundation Trust
Research and Development board, deemed the IDENTIFY
study to be exempt from ethical approval and it was given
approval as a service evaluation consistent with UK Health
Research Authority guidelines. Participating institutions
registered the study locally with their Research and
Development, and approval for study participation was
granted at each centre.
This study was registered with clinicaltrials.gov
NCT03548688.
RESULTS
Of 11 059 patients assessed for eligibility, we included 10 896
patients from 110 hospitals across 26 countries (Table S2 and
Table S3 details the number of patients and cancers in each
country/site). About two-thirds (65.4%) of patients were
referred with VH and 28.9% with NVH (Fig. 1). The
remaining (5.64%) patients had NH and reasons for their
referral are given in Table S4.
Patient demographics and clinical characteristics are shown in
Table 1. The cancer classifications are detailed in Table S5. Of
the 10 896 patients, 2257 had cancer (overall prevalence of
20.7%, 95% CI 20.0–21.5), the majority of which was bladder
cancer (n = 1951), with a prevalence of 17.9% (95% CI 17.2–
18.6). The other types of cancer were less common;
prevalence of UTUC (n = 128) was 1.17% (95% CI 0.99–
*Some patients were found to have more than one type of cancer, therefore the total number of patients with cancer 
(i.e. ‘All cancers’) do not equal the sum of the different types of cancer within that box. 
Patients assessed for 
eligibility (n=11059)
Excluded (n=163):
-Not met inclusion criteria: 6
-Withdrawn: 134 patients from 20 
centres 





All cancers* (n=1853, 26.0%)
- Bladder cancer: 1598 (22.4%)
- Upper Tract Urothelial Cancer: 114 
(1.60%)
-Renal cancer: 90 (1.26%)




All cancers* (n=201, 6.38%)
- Bladder cancer: 165 (5.23%)
- Upper Tract Urothelial Cancer: 9 
(0.29%)
-Renal cancer: 13 (0.41%)
-Prostate cancer: 17 (1.23%)
No haematuria 
n=614 (5.64%)
All cancers* (n=203, 33.1%)
- Bladder cancer: 188 (30.6%)
- Upper Tract Urothelial Cancer: 5 
(0.81%)
-Renal cancer: 4 (0.65%)
-Prostate cancer: 9 (2.34%)
Fig. 1 Cohort flow diagram. *Some patients were found to have more than one type of cancer, therefore the total number of patients with cancer (i.e.
‘All cancers’) do not equal the sum of the different types of cancer within that box.
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Table 1 Patient demographics and clinical characteristics.















Total 10896 8639 (79.3) 2257 (20.7) 1951 (17.9) 128 (1.17) 107 (0.98) 124/6807 (1.82)
Type of haematuria
NVH 3152 (28.9) 2951 (34.2) 201 (8.91) 165 (8.46) 9 (7.03) 13 (12.1) 17 (13.7)
VH 7130 (65.4) 5277 (61.1) 1853 (82.1) 1598 (81.9) 114 (89.1) 90 (84.1) 98 (79.0)
NH 614 (5.64) 411 (4.76) 203 (8.99) 188 (9.64) 5 (3.91) 4 (3.74) 9 (7.26)
Age, years
Mean (SD) 64.4 (14.4) 62.8 (14.8) 70.4 (12.0) 70.5 (11.8) 71.6 (11.8) 64.6 (13.0) 72.7 (11.0)
<35 413 (3.79) 394 (4.56) 19 (0.84) 15 (0.77) 2 (1.56) 1 (0.93) 1 (0.81)
35–39 261 (2.40) 242 (2.80) 19 (0.84) 17 (0.87) 1 (0.78) 2 (1.87) 0 (0)
40–44 379 (3.48) 353 (4.09) 26 (1.15) 23 (1.18) 1 (0.78) 2 (1.87) 1 (0.81)
45–49 621 (5.70) 566 (6.55) 55 (2.44) 45 (2.31) 1 (0.78) 6 (5.61) 3 (2.42)
50–54 922 (8.46) 819 (9.48) 103 (4.56) 83 (4.25) 4 (3.12) 15 (14.0) 1 (0.81)
55–59 1137 (10.4) 988 (11.4) 149 (6.60) 122 (6.25) 10 (7.81) 14 (13.1) 5 (4.03)
60–64 1322 (12.1) 1067 (12.4) 255 (11.3) 226 (11.6) 11 (8.59) 14 (13.1) 11 (8.87)
65–69 1432 (13.1) 1092 (12.6) 340 (15.1) 296 (15.2) 18 (14.1) 12 (11.2) 24 (19.4)
70–74 1514 (13.9) 1112 (12.9) 402 (17.8) 344 (17.6) 24 (18.8) 17 (15.9) 22 (17.7)
≥75 2894 (26.6) 2005 (23.2) 889 (39.4) 780 (40.0) 56 (43.8) 24 (22.4) 56 (45.2)
Sex
Female 4080 (37.4) 3558 (41.2) 522 (23.1) 463 (23.7) 42 (32.8) 26 (24.3) NA
Male 6807 (62.5) 5075 (58.8) 1732 (76.7) 1485 (76.1) 86 (67.2) 81 (75.7) 124 (100)
Other 9 (0.08) 6 (0.07) 3 (0.13) 3 (0.15) 0 (0) 0 (0) 0 (0)
Smoking
Never smoked 4877 (44.8) 4219 (48.8) 658 (29.2) 526 (27.0) 41 (32.0) 45 (42.1) 61 (49.2)
Ex-smoker 3231 (29.7) 2374 (27.5) 857 (38.0) 765 (39.2) 40 (31.3) 39 (36.5) 36 (29.0)
Current smoker 1991 (18.3) 1421 (16.5) 570 (25.3) 516 (26.5) 37 (28.9) 17 (15.9) 12 (9.68)
Unknown 797 (7.31) 625 (7.23) 172 (7.62) 144 (7.38) 10 (7.81) 6 (5.61) 15 (12.1)
Smoking pack years (n = 6019)
0–10 996 (16.5) 792 (17.9) 204 (12.8) 174 (12.2) 15 (17.2) 9 (14.5) 8 (12.7)
11–20 1060 (17.6) 727 (16.5) 333 (20.8) 308 (21.6) 18 (20.7) 8 (12.9) 9 (14.3)
>20 1921 (31.9) 1242 (28.1) 679 (42.5) 616 (43.2) 34 (39.1) 29 (46.8) 19 (30.2)
Unknown 1049 (17.4) 865 (19.6) 184 (11.5) 160 (11.2) 10 (11.5) 9 (14.5) 9 (14.3)
Missing 993 (16.5) 794 (18.0) 199 (12.4) 167 (11.7) 10 (11.5) 7 (11.3) 18 (28.6)
UTI history
None 8334 (76.5) 6340 (73.4) 1994 (88.4) 1724 (88.4) 114 (89.1) 96 (89.7) 106 (85.2)
Single 1291 (11.9) 1147 (13.3) 144 (6.38) 120 (6.15) 9 (7.03) 6 (5.61) 12 (9.68)
Recurrent 1127 (10.3) 1028 (11.9) 99 (4.39) 87 (4.46) 5 (3.91) 5 (4.67) 6 (4.84)
Missing 144 (1.32) 124 (1.44) 20 (0.89) 20 (1.03) 0 (0) 0 (0) 0 (0)
UTI at time of
haematuria
n/N with UTI (%)
1580/2418 (65.3) 1437/2175 (66.1) 143/243 (58.8) 118/207 (57.0) 10/14 (71.4) 8/11 (72.7) 10/18 (55.6)
Body mass index (BMI), kg/m2
Mean (SD) 27.4 (5.67) 27.7 (5.94) 26.8 (4.84) 26.7 (4.80) 26.3 (4.77) 27.9 (5.89) 26.9 (4.73)
Not obese (BMI <30) 3868 (35.5) 2685 (31.1) 1183 (52.4) 1051 (53.9) 71 (55.5) 41 (38.3) 53 (42.7)
Obese (BMI ≥30) 1346 (12.4) 1045 (12.1) 301 (13.3) 261 (13.4) 14 (11.0) 18 (16.8) 13 (10.5)
Missing 5682 (52.1) 4909 (56.8) 773 (34.3) 639 (32.8) 43 (33.6) 48 (44.9) 58 (46.8)
Ethnicity
White 8469 (77.7) 6574 (76.1) 1895 (84.0) 1648 (84.5) 112 (87.5) 88 (82.2) 96 (77.4)
Asian 1239 (11.4) 1033 (12.0) 206 (9.13) 185 (9.48) 6 (4.69) 8 (7.48) 9 (7.26)
Black 305 (2.80) 282 (3.26) 23 (1.02) 14 (0.72) 3 (2.34) 3 (2.80) 3 (2.42)
Other 533 (4.89) 446 (5.16) 87 (3.85) 65 (3.33) 4 (3.12) 5 (4.67) 14 (11.3)
Missing 350 (3.21) 304 (3.52) 46 (2.04) 39 (2.00) 3 (2.34) 3 (2.80) 2 (1.61)
Occupational risk*
No 9061 (83.2) 7211 (83.5) 1850 (82.0) 1592 (81.6) 105 (82.0) 94 (87.9) 103 (83.1)
Yes 420 (3.85) 290 (3.36) 130 (5.76) 121 (6.20) 5 (3.91) 2 (1.87) 6 (4.84)
Unknown 1060 (9.73) 828 (9.58) 232 (10.3) 201 (10.3) 15 (11.7) 9 (8.41) 11 (8.87)
Missing 355 (3.26) 310 (3.59) 45 (1.99) 37 (1.90) 3 (2.34) 2 (1.87) 4 (3.23)
Medication risk†
No 9757 (89.6) 7734 (89.5) 2023 (89.6) 1752 (89.9) 110 (85.9) 97 (90.7) 113 (91.1)
Yes 84 (0.77) 62 (0.72) 22 (0.97) 18 (0.92) 2 (1.56) 1 (0.93) 1 (0.81)
Unknown 672 (6.17) 506 (5.86) 166 (7.35) 145 (7.43) 11 (8.59) 7 (6.54) 6 (4.84)
Missing 383 (3.52) 337 (3.90) 46 (2.04) 36 (1.85) 5 (3.91) 2 (1.87) 4 (3.23)
Dysuria
No 8391 (77.0) 6528 (75.6) 1863 (82.5) 1601 (82.1) 116 (90.6) 88 (82.2) 100 (80.65)
Yes 2270 (20.8) 1907 (22.1) 363 (16.1) 320 (16.4) 11 (8.56) 19 (17.8) 24 (19.4)
Missing 235 (2.16) 204 (2.36) 31 (1.37) 30 (1.54) 1 (0.78) 0 (0) 0 (0)
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1.39), renal cancer (n = 107) was 0.98% (95% CI 0.80–1.29),
and prostate cancer (n = 124) was 1.82% (95% CI 1.51–2.17).
Proportions of urinary tract cancers (bladder cancer, UTUC,
and renal cancer) by type of haematuria for different age
groups, sex, and smoking status are shown in Table 2a and 2b.
Patients with VH had an overall cancer prevalence of 26.0%
compared to 6.38% in patients with NVH. Irrespective of the
type of haematuria, the proportion of cancer appeared to
increase with age, those with a smoking history, and in males.
In patients with NVH there were no cancers in those aged
<35 years, nor renal cancers in those aged <40 years or
UTUCs those aged <60 years. In patients with VH, the overall
cancer prevalence was 17.8% in never smokers vs 35.7% in
current smokers, and 19.9% in females vs 28.5% in males.
In patients with any haematuria (VH or NVH) the adjusted
prevalence of bladder cancer was 24.7% (95% CI 19.1–30.2) in
comparison to unadjusted prevalence of 17.1% (95% CI 16.4–
17.9) (Table 3). Adjusted prevalence of bladder cancer was also
higher than the unadjusted prevalence in both the VH and
NVH groups. Adjusted and unadjusted prevalence rates were
similar for UTUC, renal cancer, and prostate cancer.
The multivariable mixed-effects logistic regression used for
adjustment showed that VH, older age, male sex, and
smoking were significant risk markers for ‘all cancers’
(Table 4). Considering each cancer type separately, VH was
significantly associated with bladder cancer (odds ratio [OR]
3.50, 95% CI 2.88–4.26; P < 0.001), UTUC (OR 4.23, 95% CI
2.09–8.55; P < 0.001), and renal cancer (OR 2.56, 95% CI
1.40–4.67; P < 0.001). Increasing age (OR 1.04, 95% CI 1.03–
1.06; P < 0.001) also increased the odds of bladder cancer,
UTUC, and prostate cancer. Compared to patients who had
never smoked, ex-smokers and current smokers had
significantly increased odds of bladder cancer and UTUC,
with current smokers having more than a three-fold increase
in the odds of bladder cancer (OR 3.18, 95% CI 2.67–3.78).
Male sex was associated with bladder cancer (OR 1.15, 95%
CI 1.00–1.34; P = 0.058) and renal cancer (OR 1.54, 95% CI
0.95–2.49; P = 0.08), but these were not statistically
significant.
DISCUSSION
The IDENTIFY study is the largest international prospective
observational study on the investigation of suspected urinary
tract cancer in secondary care. Bladder cancer was the most
common cancer, with an adjusted prevalence of 24.7% in
patients with haematuria. The rarer upper tract cancers,
UTUC and renal cancer, accounted for ~1% each. Urinary
tract cancers were more prevalent in patients with VH, men,
older patients, and those with a smoking history. These
factors were significantly associated with urinary tract cancer
on multivariable analysis. There were no cancers in the NVH
group in patients aged <35 years for bladder cancer or those
aged <60 years for UTUC. These data can become the new
reference standard to inform international guidelines for the
investigation of urinary tract cancer.
The main strength of the present study is its design and
robust methods in estimating an adjusted prevalence of
disease. The study’s large sample size allowed for estimates
with a high degree of precision, especially in rarer cancers.
The international nature of the present study and the breadth
of countries improves on previous single-centre studies in this
field [3,8,9]. To our knowledge, we are the first to adjust
cancer prevalence for well-known patient risk markers and
geographical variation. Our methods show transparency of
cancer classification, and we have minimised selection bias by
including an international population that would typically be
encountered in clinical practice.
A multicentre study in secondary care reported a much lower
bladder cancer crude prevalence of 8.0% in patients being
investigated with haematuria [3]. However, the primary
objective of that previous study was not to determine the
prevalence of urinary tract cancer, nor was the study designed
to. Patients were recruited as part of a urinary biomarker
Table 1 (continued)
















No 5920 (54.3) 4470 (51.7) 1450 (64.2) 1265 (64.8) 89 (69.5) 63 (58.9) 69 (55.7)
Yes 621 (5.70) 438 (5.07) 183 (8.11) 157 (8.05) 13 (10.2) 13 (12.1) 7 (5.65)
Missing 4355 (40.0) 3731 (43.2) 624 (27.7) 529 (27.1) 26 (20.3) 31 (29.0) 48 (38.7)
Previous haematuria evaluation
No 9709 (89.1) 7607 (88.1) 2102 (93.1) 1823 (93.4) 119 (93.0) 100 (93.5) 109 (87.9)
Yes 1053 (9.66) 917 (10.6) 136 (6.03) 109 (5.59) 9 (7.03) 7 (6.54) 15 (12.1)
Missing 134 (1.23) 115 (1.33) 19 (0.84) 19 (0.97) 0 (0) 0 (0) 0 (0)
NA, not applicable; WCC, white cell count. Percentages are column percentages except in the first row (‘Total’), which are row percentages.
*Defined as exposure to dyes, rubber, textiles, pesticides. †e.g. cyclophosphamide, pioglitazone.
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clinical trial for bladder cancer, so the observed prevalence is
likely influenced by patient selection. Furthermore, their
reference standard for upper tract cancer diagnosis was based
solely on MDT meeting consensus after review of imaging.
Conversely, we determined detailed cancer positive and
negative classification from the offset and considered
histopathological diagnosis, as well as the outcome of local
MDT meetings, for each type of cancer. We also reported the
proportion of cancer-positive cases determined by each of
these (Table S5).
Other cohort studies have also reported lower bladder cancer
rates of 10.3–11.9%, but these have been smaller single-centre
retrospective studies [8,9]. These also lack transparency in
their classification of disease outcome and smoking history
was not recorded in the study by Edwards et al. [8].
Furthermore, the proportions of patients with VH and NVH
in these studies were almost equal, reflecting a selected
population. However, in our present study that is reflective of
an international population, two-thirds of patients had VH,
and so prevalence will be expectedly higher.
Table 2 Proportion of urinary tract cancers stratified by type of haematuria.
(a) Visible haematuria, n (%)
Total patients All cancers Bladder cancer UTUC Renal cancer
Total 7130 1853 (26.0) 1598 (22.4) 114 (1.60) 90 (1.26)
Age
<35 275 (3.86) 17 (6.18) 13 (4.73) 2 (0.73) 1 (0.36)
35–39 164 (2.30) 13 (7.93) 12 (7.32) 0 (0) 2 (1.22)
40–44 228 (3.20) 22 (9.65) 19 (8.33) 1 (0.44) 2 (0.88)
45–49 371 (5.20) 44 (11.9) 37 (9.97) 1 (0.27) 5 (1.35)
50–54 524 (7.32) 84 (16.0) 67 (12.8) 4 (0.76) 13 (2.48)
55–59 671 (9.41) 112 (17.0) 91 (13.6) 10 (1.49) 9 (1.34)
60–64 827 (11.6) 210 (25.4) 186 (22.5) 9 (1.09) 11 (1.36)
65–69 930 (13.1) 273 (29.4) 239 (25.7) 15 (1.61) 11 (1.18)
70–74 1012 (14.2) 333 (32.9) 283 (28.0) 22 (2.17) 16 (1.58)
≥75 2127 (29.8) 745 (35.0) 651 (30.6) 50 (2.35) 20 (0.94)
Sex
Female 2083 (29.2) 415 (19.9) 367 (17.6) 36 (1.73) 20 (0.96)
Male 5043 (70.7) 1437 (28.5) 1230 (24.4) 78 (1.55) 70 (1.39)
Other 4 (0.06) 1 (25.0) 1 (25.0) 0 (0) 0 (0)
Smoking
Never 3011 (42.2) 535 (17.8) 431 (14.3) 38 (1.26) 35 (1.16)
Ex-smoker 2238 (31.4) 702 (31.4) 621 (27.8) 35 (1.56) 33 (1.47)
Current Smoker 1321 (18.5) 471 (35.7) 424 (32.1) 32 (2.42) 16 (1.21)
Unknown 560 (7.85) 145 (25.9) 122 (21.8) 9 (1.61) 6 (1.07)
(b) Non-visible haematuria, n (%)
Total patients All cancers Bladder cancer UTUC Renal cancer
Total 3152 201 (6.38) 165 (5.23) 9 (0.29) 13 (0.41)
Age
<35 117 (3.71) 0 0 (0) 0 (0) 0 (0)
35–39 84 (2.67) 1 (1.19) 1 (1.19) 0 (0) 0 (0)
40–44 134 (4.25) 1 (0.75) 1 (0.75) 0 (0) 0 (0)
45–49 227 (7.20) 5 (2.20) 2 (0.88) 0 (0) 1 (0.44)
50–54 352 (11.2) 9 (2.56) 8 (2.27) 0 (0) 0 (0)
55–59 399 (12.7) 25 (6.27) 19 (4.76) 0 (0) 5 (1.25)
60–64 432 (13.7) 24 (5.56) 21 (4.86) 1 (0.23) 2 (0.46)
65–69 411 (13.0) 27 (6.57) 20 (4.87) 3 (0.73) 1 (0.24)
70–74 408 (13.0) 36 (8.82) 31 (7.60) 1 (0.25) 1 (0.25)
≥75 587 (18.6) 52 (12.4) 62 (10.6) 4 (0.68) 3 (0.51)
Sex
Female 1770 (56.2) 54 (3.05) 46 (2.60) 4 (0.23) 5 (0.28)
Male 1380 (43.8) 147 (10.7) 119 (8.62) 5 (0.36) 8 (0.58)
Other 2 (0.06) 0 (0) 0 (0) 0 (0) 0 (0)
Smoking
Never 1640 (52.0) 69 (4.21) 46 (2.80) 3 (0.18) 9 (0.55)
Ex-smoker 768 (24.4) 66 (8.59) 59 (7.68) 3 (0.39) 3 (0.39)
Current Smoker 560 (17.8) 50 (8.93) 47 (8.39) 3 (0.54) 1 (0.18)
Unknown 184 (5.84) 16 (8.70) 13 (7.07) 0 (0) 0 (0)
Percentages are row percentages (n/N patients), except for the first column (‘Total patients’) which are column percentages.
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The unadjusted prevalence of bladder cancer (17.1%) was lower
than the adjusted prevalence (24.7%). Country-specific cancer
prevalence varied greatly, and the adjustment for country had the
biggest effect on prevalence. We suspect the low unadjusted
prevalence is due to a relatively low cancer prevalence in the
largest contributing country (UK) compared to the rest of the
cohort. Adjusting for this effect provided a more accurate
estimate of prevalence. This highlights the likely underestimation
of prevalence in previous studies where this adjustment has not
been carried out, and the problem of single-centre studies when
there is so much variation even within a country.
Patients referred with NH were included in the study to
minimise selection bias and reflect clinical practice. The high
proportion of pre-referral suspected abnormality on imaging
explains the high 33.1% prevalence of cancer in this group.
Clinicians should therefore have a high index of suspicion of
urinary tract cancer in patients being referred following
abnormal imaging. However, this group made up a small
proportion (5.64%) of the cohort and further evaluation is
warranted to shed light on potential factors that can improve
the diagnostic efficiency of urinary tract cancer in patients
with NH.
Table 3 Adjusted and unadjusted cancer prevalence estimates by type of haematuria and cancer.
Patient group Cancer type Unadjusted prevalence, % (95% CI) Adjusted prevalence, % (95% CI)
All patients with haematuria All cancers 20.0 (19.2–20.8) 28.2 (22.3–34.1)
Bladder cancer 17.1 (16.4–17.9) 24.7 (19.1–30.2)
UTUC 1.20 (1.00–1.43) 1.14 (0.77–1.52)
Renal cancer 1.00 (0.83–1.21) 1.05 (0.80–1.29)
Prostate cancer 1.79 (1.49–2.14) 1.75 (1.32–2.18)
Visible haematuria All cancers 26.0 (25.0–27.0) 33.4 (26.7–40.0)
Bladder cancer 22.4 (21.5–23.4) 29.3 (23.0–35.8)
UTUC 1.60 (1.33–1.92) 1.47 (0.98–1.96)
Renal cancer 1.26 (1.03–1.55) 1.27 (0.95–1.58)
Prostate cancer 1.94 (1.60–2.36) 1.88 1.39–2.37)
Non-visible haematuria All cancers 6.38 (5.58–7.28) 15.5 (10.8–20.2)
Bladder cancer 5.23 (4.51–6.07) 13.1 (8.82–17.4)
UTUC 0.29 (0.15–0.54) 0.36 (0.10–0.62)
Renal cancer 0.41 (0.24–0.70) 0.50 (0.22–0.79)
Prostate cancer 1.23 (0.77–1.96) 1.25 (0.56–1.93)
Prevalence was adjusted for sex, age, smoking status and country and centre effects using a mixed-effect multivariable logistic regression. For the
analyses of all patients with haematuria, we also adjusted for type of haematuria. The total number of patients in the unadjusted analysis was
10 282 (the NH group was excluded in this analysis), and for the adjusted analysis was 9531, except when estimating prostate cancer prevalence
where the total number of patients in the unadjusted analysis was 6429 and for the adjusted analysis was 5938.









OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Age 1.04 (1.03–1.05) <0.001 1.04 (1.03–1.05) <0.001 1.04 (1.03–1.06) <0.001 1.00 (0.98–1.01) 0.55 1.04 (1.03–1.06) <0.001
Haematuria
NVH 1.00 1.00 1.00 1.00 1.00
VH 3.47 (2.90–4.15) <0.001 3.50 (2.88–4.26) <0.001 4.23 (2.09–8.55) <0.001 2.56 (1.40–4.67) <0.001 1.53 (0.85–2.74) 0.16
Sex
Female 1.00 1.00 1.00 1.00 – –




1.00 1.00 1.00 1.00 1.00
Ex-smoker 1.85 (1.61–2.13) <0.001 2.19 (1.88–2.55) <0.001 1.14 (0.72–1.81) 0.57 1.11 (0.70–1.76) 0.44 0.53 (0.34–0.83) 0.005
Current
smoker
2.70 (2.30–3.18) <0.001 3.18 (2.67–3.78) <0.001 2.49 (1.53–4.04) <0.001 0.83 (0.47–1.47) 0.52 0.40 (0.20–0.79) 0.009
Random effects variance
Country 0.64 (0.27–0.28) 0.67 (0.30–1.49) 0.04 (0.00–4.74) 0.00 0.00
Centre 0.38 (0.08–0.25) 0.42 (0.28–0.64) 0.34 (0.08–1.40) 0.25 (0.05–1.21) 0.45 (0.17–1.23)
Intraclass correlation
Country 0.15 (0.07–28.3) 0.15 (0.07–28.8) 0.01 (0.00–0.58) 0.00 0.00
Centre 0.27 (0.17–33.9) 0.25 (0.17–0.35) 0.10 (0.04–0.27) 0.07 (0.02–0.27) 0.12 (0.05–0.27)
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One limitation of the present study is generalisability to
primary care populations. The study was conducted in
secondary care and we are not aware of the effects of triage
that occurred at a primary care level. Further limitations
include any other unknown confounding variables associated
with detection of cancer that we did not adjust for. We
focussed on variables chosen a priori with biological
plausibility for having an association with cancer detection.
Future work from the IDENTIFY study will focus on
developing a cancer prediction model using key patient
characteristics to risk-stratify patients, in addition to
diagnostic test evaluation, to develop a patient-specific
diagnostic algorithm for haematuria. It is hoped that by
adopting such algorithms, patients with suspected urinary
tract cancer may receive more tailored investigations based on
their individual risk, which focus on the detection of cancers,
whilst minimising unnecessary over-investigation. In addition,
further evaluation of the IDENTIFY data will explore: the
variation in prevalence between countries, the effect of
different protocols for haematuria and different healthcare
systems on cancer prevalence, the patient group with NH, the
different grades of NVH, and the implication of different
international referral guidelines on this cohort.
In conclusion, the present study provides a robust
contemporary evaluation of cancer prevalence in patients
referred to secondary care with suspected urinary tract
cancer. Adjustment for patient risk markers and geographical
variation resulted in more accurate cancer prevalence.
Patients are commonly referred with VH, and bladder cancer
is the most prevalent cancer.
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